198 related articles for article (PubMed ID: 25542901)
1. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
[TBL] [Abstract][Full Text] [Related]
2. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
3. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
5. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
6. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
7. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
8. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract][Full Text] [Related]
9. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
10. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract][Full Text] [Related]
11. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
Capparelli C; Rosenbaum S; Berman-Booty LD; Salhi A; Gaborit N; Zhan T; Chervoneva I; Roszik J; Woodman SE; Davies MA; Setiady YY; Osman I; Yarden Y; Aplin AE
Cancer Res; 2015 Sep; 75(17):3554-67. PubMed ID: 26206558
[TBL] [Abstract][Full Text] [Related]
12. HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
14. Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system.
Lindholm T; Cullheim S; Deckner M; Carlstedt T; Risling M
Exp Brain Res; 2002 Jan; 142(1):81-90. PubMed ID: 11797086
[TBL] [Abstract][Full Text] [Related]
15. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
16. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
17. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
18. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
19. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
20. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]